552 reports of this reaction
2.8% of all VIGABATRIN reports
#5 most reported adverse reaction
SOMNOLENCE is the #5 most commonly reported adverse reaction for VIGABATRIN, manufactured by Lundbeck Pharmaceuticals LLC. There are 552 FDA adverse event reports linking VIGABATRIN to SOMNOLENCE. This represents approximately 2.8% of all 19,478 adverse event reports for this drug.
Patients taking VIGABATRIN who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for VIGABATRIN, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for VIGABATRIN:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 552 FDA reports for VIGABATRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 2.8% of all adverse event reports for VIGABATRIN, making it a notable side effect.
If you experience somnolence while taking VIGABATRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.